Entering text into the input field will update the search result below

EMA accepts Acorda's marketing application for Parkinson's med Inbrija

May 29, 2018 8:06 AM ETAcorda Therapeutics, Inc. (ACOR) StockBy: Douglas W. House, SA News Editor
  • The European Medicines Agency (EMA) has accepted for review Acorda Therapeutics' (NASDAQ:ACOR) marketing application seeking approval for INBRIJA (levodopa inhalation powder) for the treatment of OFF periods in Parkinson's disease patients taking a carbidopa/levodopa regimen.
  • The agency's action date will be in late December based on a 210-day review period from the approximate validation date of May 29.
  • The company's U.S. marketing application is currently under FDA review with an action date of October 5.

Recommended For You

More Trending News

About ACOR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACOR--
Acorda Therapeutics, Inc.